Cannabidiol Oral Product — Competitive Intelligence Brief

Cannabidiol Oral Product (Cannabidiol Oral Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid. Area: Neurology, Psychiatry, Immunology.

marketed Cannabinoid Multiple targets including CB1/CB2 (allosteric modulation), 5-HT1A receptor, TRPV1 channel Neurology, Psychiatry, Immunology Small molecule

Target snapshot

Cannabidiol Oral Product (Cannabidiol Oral Product) — University of Connecticut. Cannabidiol (CBD) is a non-intoxicating cannabinoid that modulates multiple molecular targets including serotonin receptors, TRPV1 channels, and endocannabinoid signaling to produce anti-inflammatory, anxiolytic, and anticonvulsant effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cannabidiol Oral Product TARGET	Cannabidiol Oral Product	University of Connecticut	marketed	Cannabinoid	Multiple targets including CB1/CB2 (allosteric modulation), 5-HT1A receptor, TRPV1 channel
Marinol	DRONABINOL	Wellhouse Pharma	marketed	Cannabinoid [EPC]	Cannabinoid receptors	1985-01-01
Cesamet	NABILONE	Bausch Health	marketed	Cannabinoid [EPC]	Cannabinoid receptor 1	1985-01-01
Cannabis Sativa Oil	Cannabis Sativa Oil	Fondation pour l'accueil et l'hébérement des personnes âgées	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
ultra-micronized palmitoylethanolamide	ultra-micronized palmitoylethanolamide	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	marketed	Endocannabinoid-like lipid mediator / PPAR-α agonist	PPAR-α; mast cell stabilization
Nabilone Oral Capsule	Nabilone Oral Capsule	Centre for Addiction and Mental Health	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Cesamet™ (nabilone)	Cesamet™ (nabilone)	NEMA Research, Inc.	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid class)

1. Wayne State University · 3 drugs in this class
2. Hôpital le Vinatier · 1 drug in this class
3. Montefiore Medical Center · 1 drug in this class
4. OMNI Medical Services, LLC · 1 drug in this class
5. Gold Coast Hospital and Health Service · 1 drug in this class
6. Stero Biotechs Ltd. · 1 drug in this class
7. University of California, San Diego · 1 drug in this class
8. University of Connecticut · 1 drug in this class
9. Staci Gruber, Ph.D. · 1 drug in this class